Brief: Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application

Vera Therapeutics

07/01/2026 12:38

Jan 7 (Reuters) - Vera Therapeutics Inc VERA.O:

VERA THERAPEUTICS ANNOUNCES U.S. FDA GRANTED PRIORITY REVIEW TO BIOLOGICS LICENSE APPLICATION FOR ATACICEPT FOR TREATMENT OF ADULTS WITH IGA NEPHROPATHY

VERA THERAPEUTICS INC: FDA ASSIGNED PDUFA TARGET ACTION DATE OF JULY 7, 2026.

VERA THERAPEUTICS INC:  FDA ASSIGNED PDUFA TARGET ACTION DATE OF JULY 7, 2026.

VERA THERAPEUTICS INC - ATACICEPT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR IGAN

Source text: ID:nGNX1PWPWQ

Further company coverage: VERA.O

 ((Reuters.Briefs@thomsonreuters.com;))